Vaginal medical device is effective against infections and vaginal dryness
Vulvovaginal infections caused by Candida albicans are among the leading causes of intimate discomfort in women, with recurring symptoms such as itching, burning, leucorrhoea, and pain during intercourse. They affect women of all ages and may occur even in the absence of evident risk factors. These infections are often associated with vaginal dryness, pH imbalance, and alterations of the vaginal flora, which worsen the clinical picture and significantly impact quality of life.
To effectively and safely address these issues, Gruppo FarmaImpresa developed Lattawin Gel, a topical vaginal medical device (FT.CE.113). Its efficacy has been confirmed by two independent clinical studies, with particular attention to the reduction of Candida colonization and the improvement of subjective symptoms.
Clinical Study: Lattawin Gel reduces swab test positivity for Candida
In the first clinical study, 30 women with symptoms of vaginal candidiasis were treated with Lattawin Gel for 4 weeks. Treatment efficacy was assessed through both clinical symptoms (Total Symptoms Score – TSS) and vaginal swab tests to detect the presence of Candida albicans.
Results showed that swab test positivity decreased from 100% to 3.6%, with extremely high statistical significance (p < 0.0001). In parallel, the TSS score dropped from 7.9 to 0.56, showing marked improvements in symptoms such as burning, dysuria, leucorrhoea, and dyspareunia.
Beyond symptomatic and microbiological remission, patients reported a strong improvement in quality of life, measured using PCS-12 and MCS-12 questionnaires, with significant progress both in physical (p = 0.00016) and mental components (p = 0.0013).
Lattawin Gel and vaginal dryness: results from the VSQ study
A second observational clinical study evaluated the efficacy of Lattawin Gel in treating vulvovaginal dryness, involving 20 women. The reference parameter was the Vulvovaginal Symptoms Questionnaire (VSQ), a validated tool for detecting subjective symptoms, emotional impact, and sexual quality of life.
After 4 weeks of treatment, the mean VSQ score decreased from 4.10 to 0.15, with an average improvement of 4.05 points (p < 0.001). 95% of patients achieved complete remission of symptoms, and all showed significant improvements in itching, dryness, altered vaginal discharge, and odors. Emotional and sexual life dimensions also benefited from the treatment.
Who is Lattawin Gel for?
Lattawin Gel is indicated in the following conditions:
- Vulvovaginal candidiasis, including recurrent forms
- Vaginal dryness due to menopause, breastfeeding, stress, or medications
- Intimate irritation with burning, itching, or post-coital discomfort
- Alterations of the vaginal microbiota and pH
- Discomfort during sexual intercourse
The product is suitable for women of childbearing age, menopausal, or postpartum, and can also be used as supportive therapy alongside conventional antifungal treatments.
Why choose Lattawin Gel?
Lattawin Gel is a medical device with clinically proven efficacy in two independent studies conducted by Gruppo FarmaImpresa. Results highlight:
- 96% reduction in vaginal swab positivity for Candida
- Symptomatic remission in 95% of vaginal dryness cases
- Significant improvement in intimate and sexual quality of life
Lattawin Gel is ready for your business
If you are a company in the healthcare, gynecology, or pharmaceutical distribution sector, Lattawin Gel is a concrete opportunity to expand your portfolio.
The device is available ready-to-market or in private label, with full support for customization, registration, and international distribution.
Your strategic partner in nutraceutical and cosmetic innovation
We provide complete Contract Development and Manufacturing (CDMO) services for the design, production, and commercialization of:
-
Food supplements
-
Substance-based medical devices
-
Dermocosmetics
